Dr. Steven Zheng is a Professor and Chief, Division of Cancer Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey. He received his Ph.D. from Harvard University in 1993 (with Joan Ruderman) and his postdoctoral training at Harvard (with Stuart Schreiber). He became a faculty member at Washington University before moving to Rutgers. His research has focused on understanding the biochemical mechanisms of nutrient signaling in cancer and metabolic diseases and developing new therapies. Dr. Zheng discovered that mTOR can act as a transcription factor, and he elaborated on knowledge of the mechanisms underpinning nuclear mTOR signaling in controlling transcription, chromatin dynamics, and genomic stability. His laboratory has also shed light on the therapeutic response and resistance to rapamycin and mTOR kinase inhibitors in colorectal and liver cancers. For the past 25 years, Dr. Zheng has been continuously supported by NIH/NCI R01 grants. He has served on numerous NIH and other national and international review panels.